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Abstract
To assess a potential diagnostic and therapeutic biomarker for age-related macular degeneration (AMD), we sequenced the
complement factor I gene (CFI) in 2266 individuals with AMD and 1400 without, identifying 231 individuals with rare genetic
variants. We evaluated the functional impact bymeasuring circulating serum factor I (FI) protein levels in individuals with and
without rare CFI variants. The burden of very rare (frequency <1/1000) variants in CFI was strongly associated with disease
(P = 1.1 × 10−8). In addition, we examined eight coding variants with counts ≥5 and saw evidence for association with AMD in
three variants. Individuals with advanced AMD carrying a rare CFI variant had lowermean FI comparedwith non-AMD subjects
carrying avariant (P < 0.001). Further newevidence that FI levels driveAMDrisk comes fromanalyses showing individualswith a
CFI rare variant and low FIweremore likely to have advancedAMD (P = 5.6 × 10−5). Controlling for covariates, low FI increased the
riskof advancedAMDamong thosewith avariant comparedwith individualswithout advancedAMDwith a rareCFI variant (OR
13.6, P = 1.6 × 10−4), and also compared with control individuals without a rare CFI variant (OR 19.0, P = 1.1 × 10−5). Thus, low FI
levels are strongly associated with rare CFI variants and AMD. Enhancing FI activity may be therapeutic and measuring FI
provides a screening tool for identifying patients who are most likely to benefit from complement inhibitory therapy.
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Introduction
Age-related macular degeneration (AMD) is a common disease
with multifactorial etiology (1,2). In addition to behavioral and
environmental factors, >20 common genetic loci have been con-
firmed to be associated with AMD, includingmany in the comple-
ment system (3–5). We have recently described strongly
associated, rare, functionally significant variants in the comple-
ment factor H gene (CFH) (6,7), further suggesting that impaired
complement regulation is central to the pathogenesis ofAMD (7,8).
Recently, investigators have identified association of rare gen-
etic variants in the complement factor I gene (CFI) with advanced
AMD (AAMD) (9–11). These studies targeted CFI for sequencing
because a common intronic variant in this gene was previously
associated with risk of AAMD (12). The factor I (FI) protein is a
serum serine protease that is a critical regulator of alternative
pathway of complement activation by cleaving C3b in the pres-
ence of its cofactors (13,14).
The definition of the genetic factors driving AMD risk has led
to the testing of novel therapeutic agents, including complement
inhibitors. Results to date, however, have suggested that only a
subgroup of individuals may respond to complement inhibition
(15). That a diseasewith several disparate genetic predispositions
should respond divergently to specific therapies should not be
surprising. Personalized therapy for AMD based on an indivi-
dual’s genotype should be the ultimate goal; however, to date
the majority of rare CFI genetic variants described in AMD pa-
tients are missense mutations of uncertain biologic relevance.
Considering the loss-of-function CFI variant association with
AMD, the potential of agents that prevent C3 activation (15) or
supplement FI activity (16) to reduce the risk or progression of
AMD and the need for better biomarkers, serum FI is a promising
biomarker for disease diagnosis, prognosis and assessment of
therapeutic efficacy.
We therefore interrogated consequences of these rare asso-
ciated variants by studying FI antigenic levels in the circulation.
We demonstrate that low serum FI levels are significantly
associated with rare CFI variants and AAMD and suggest that
this group of patients is most likely to benefit from complement
inhibitory therapy (15) or supplementation with FI (16).
Results
CFI genetic analysis
In our study of 3666 AAMD and non-AAMD individuals (Fig. 1), 71
different non-synonymousCFI variantswere detected among 231
individuals (Supplementary Material, Tables S1–S4), including
ones classified as benign, possibly damaging, probably dam-
aging, or loss-of-function by PolyPhen2. Variants classified as
loss-of-function or probably damaging among variants with
counts <5 in AAMD and non-AAMD (45 in AAMD versus 3 in
non-AAMD) were significantly related to AMD (P = 6.1 × 10−7)
(Supplementary Material, Table S4). Overall, there were far
more rare, non-synonymous CFI variants in all categories com-
bined in the AAMD group than the non-AAMD group (80 versus
10, P = 1.1 × 10−8) (Table 1; Supplementary Material, Table S4).
Underscoring the matching of the case and control groups used
in the sequencing analysis for ancestry and data quality, syn-
onymous variants in CFI showed no difference (Table 1; Supple-
mentary Material, Table S4).
In addition, we examined the eight CFI variantswith counts in
AAMD or non-AAMD groups ≥5. No individual CFI genetic vari-
ant was highly associated with AAMD, although three were
nominally associated: p.P553S (benign) with odds ratio (OR) of
2.69, P = 0.027; p.R406H (possibly damaging), OR 0.10, P = 0.015;
and p.A240G (probably damaging), OR 7.43, P = 0.023 (Table 2;
Supplementary Material, Tables S1–S3). This number of AAMD-
associated variants (three of eight) is higher than would be ex-
pected by chance (P = 5.8 × 10−3).
Of the 209 individuals who had serum analyses, 114 subjects
had a rare genetic variant in CFI, of which 79 (69%) had AAMD.
These rare genetic variants occurred throughout the gene with
amino acid changes in both heavy and light chains of FI and
with no obvious mutational hot spots (Supplementary Material,
Fig. S1 and Tables S1, S2).
Analysis of CFI rare variant carriers
Functional consequences of these rare variants were assessed by
evaluating serum FI antigenic measurements. Table 2 displays
the FI serum levels for eight individual CFI variants analyzed
for association with AAMD. Among the five individuals with
the p.A240G risk variant and classified as probably damaging
(all with AAMD), four of the five had low serum FI levels. All indi-
viduals carrying the p.P553S risk variant and classified as benign
(eight AAMD, one non-AAMD) had normal FI levels. Among the
three individuals with the protective p.R406H variant classified
as possibly damaging (one AAMD, two non-AAMD), the serum
FI levels were normal. The previously reported p.G119R risk vari-
ant (9,11) did not formally reach statistical significance in our
study; however, all four carriers of this variant were AAMD
cases and had low FI levels, consistent with an association.
As shown in Figure 2, the average serum FI level in those with
AAMD and a CFI variant was significantly lower than among
those without AAMD and a CFI variant (34.8 versus 44.9 µg/ml,
P < 0.001). Among individuals without a CFI variant, there was
no significant difference between AAMD (40.1 µg/ml) and the
comparison group (39.2 µg/ml). Among all individuals with
AAMD, the mean FI level was significantly lower among those
carrying a rare genetic variant (P = 0.03). A larger percentage of
individuals with AAMD and a rare CFI variant had low serum FI,
compared with the comparison groups: AAMDwithout a variant,
non-AAMD without a variant, and non-AAMD with a variant
(P < 0.001). Therefore, rare CFI variants are lowering serum FI
levels and contributing to AMD risk, whereas serum FI is not
contributing to AMD risk among individuals without a variant.
Figure 3 shows the estimated ORs for the associations among
three comparison groups defined by AAMD, rare CFI variant sta-
tus and low serum FI levels. Without adjustment for covariates,
having low serum FI strongly increased risk of AAMD among
those with a variant (OR 32.0, P = 5.3 × 10−7) compared with indi-
viduals without AAMD and without a variant. After adjustment
for age, gender, body mass index (BMI) and smoking, the OR
was 19.0, P = 1.1 × 10−5. When comparing AAMD with a variant
to AAMD without a variant, the OR’s for low serum FI were 7.8
in the unadjusted model (P = 7.5 × 10−5) and 7.2 (P = 5.1 × 10−4) for
the adjusted model. For analyses only among individuals with a
rare variant, low serum FI was associated with AAMD with OR
11.2 in the unadjusted model (P = 1.8 × 10−4) and 13.6 (P = 1.6 ×
10−4) in the adjusted model. Thus, low serum FI is a risk factor
for AAMD in association with a rare CFI variant.
Table 3 displays the distribution of variables according to
serum FI level among all subjects with a rare variant. Individuals
with low serum FI were more likely to have AAMD (94.3 versus
58.2%, P = 5.6 × 10−5).Males tended tohave lower FI levels (P = 0.02)
and there was no association with age (P = 0.68). There was also
no association with smoking or BMI (data not shown).
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As shown in Figure 4, among the 79 individuals with AAMD
and a CFI variant, 33 had low FI levels. On the other hand,
among the 35 subjects without AAMD and a CFI variant, only 2
had low FI levels. Twenty-one different genetic variants were
seen in association with low FI levels.
Figure 5 demonstrates the serum FI levels categorized by the
in silico prediction of functional consequence of the genetic vari-
ant. FI levelswere significantly lower in individualswith probably
damaging or loss-of-function CFI variants compared with those
with benign or loss-of-function variants (mean 27.7 versus
43.1 µg/ml, P < 0.001) as well as compared with those with no
CFI variant (27.7 versus 39.7 µg/ml, P < 0.001).
Analyses of common CFI variant and serum C3
In the 95 individuals with no rare genetic variants in CFI, FI levels
were assessed in relation to the common variant associated with
AMD, rs10033900, near the CFI gene (12). Themean FI level for the
21 individuals homozygous for the C allelewas 38.7 μg/ml and for
the 25 individuals homozygous for the risk allele (T) it was 38.9 μg/
ml (Supplementary Material, Fig. S2), indicating no significant
difference in FI levels related to the common CFI variant.
C3 levels were measured in 32 individuals with AAMD and a
CFI variant associated with low FI levels (type 1 CFI mutation)
and 13 individuals with grade 1 only and no CFI variants. Only
three individuals with a type 1 CFI mutation had low C3 levels
(Supplementary Material, Fig. S3). There was a positive correl-
ation between the levels of FI and C3 in these 32 individuals
with a type 1 CFI variant (R = 0.51, P = 0.003) (Supplementary
Material, Fig. S4).
Discussion
In this study, we demonstrated that individuals with AAMD and
rare CFI variants commonly have low serum FI antigenic levels.
Table 1. Pooled analysis for synonymous versus non-synonymous
rare variants with counts <5
Total
AAMD
Total
non-AMD
P-value
All non-synonymous variants 80 10 1.1 × 10−8
Synonymous variants 9 8 0.47
Figure 1. (A). Flow chart for sequencing and discovery of CFI rare variants. AAMD: advanced age-related macular degeneration. Targeted sequencing was performed on
2828 individuals, including 2421 previously sequenced unrelated AAMD cases and controls without any signs of AMD (145 individuals with CFI genetic variants) (9), and
407 additional unrelated cases and controls sequenced in the samemanner (27 new individualswithCFI genetic variants identified). Sanger sequencingwas performed on
838 individuals, including 396 caseswithAAMDand 442 controls without any signs of AMD (59 new individualswith CFI genetic variants identified). A total of 231 subjects
with CFI rare variants were identified. (B) Flow chart for selection of samples for serum analysis. In order to explore the effects of disease and CFI rare variants on serum FI
levels, we first identified individuals with a variant and with AAMD for whom serum samples were available (n = 79). We identified three comparison groups from the
sequenced individuals with similar mean ages at the time of blood draw compared with the advanced AMD cases carrying a variant: (i) subjects with AAMD but no
variant (n = 48), (ii) a group without AAMD and without a variant (n = 47) and (iii) subjects without AAMD but with a variant (n = 35). The total sample comprised 209
subjects, with 114 carrying rare CFI variants.
Human Molecular Genetics, 2015, Vol. 24, No. 13 | 3863
 at U
niversity of N
ew
castle on June 30, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
This result, observed in association with 21 variants, is highly
suggestive of a variant causing a structural effect on the mutant
protein, impairing secretion. Further, this provides compelling
data corroborating previous genetic evidence for the role of im-
paired FI-mediated regulation of the complement system’s alter-
native pathway in the pathogenesis of AMD (9–11). Among all
individuals with a rare CFI genetic variant, those with AAMD
were significantly more likely to have low FI levels (haploinsuffi-
ciency) compared with those without AAMD (13.6-fold higher).
Type 1 CFI mutations accounted for 42% of the AAMD group but
only 6% of the non- AAMD group.
In addition to its role in the pathogenesis of AMD, partial de-
ficiency (haploinsufficiency) of FI is associated with atypical
Hemolytic Uremic Syndrome (aHUS: MIM 612923) (18). FI is one
of a number of biomarkers used in aHUS to discriminate between
complement-mediated aHUS (e.g. CFI, CFH and CD46 genes)
which will respond to the complement inhibitor, Eculizumab
and the non-complement-mediated forms (e.g. DGKE gene) that
do not (19).
Twenty-one distinct genetic variants were identified in asso-
ciation with low FI levels in the AMD population. Of these
variants, 10 have been seen in aHUS patients associated with
low levels (18) (p.P50A (20–22), p.P64L (20), p.G119R (20,21,23),
p.V152M (24),p.G162D (25,26), p.N177I (27), p.A240G (22,28,29),
p.G287R (23), p.K441R (30), p.R474 (21,22,24,31)).
Among rare variants with counts ≥5, the p.A240G variant
nominally increased risk of AMD in our study. Among the five in-
dividuals with this variant and serum FI levels, four had low
Table 2. Individual rare CFI variants with counts ≥5: association with AAMD and corresponding serum FI levels
Variant OR (95% CI) P-value PolyPhen2 prediction Mean serum
FI (µg/ml)
Range serum
FI (µg/ml)
% Low serum FIa
p.A240Gb 7.43 (1.10–317.46) 0.02 Probably damaging 23.4 10.5–40.0 80 (4/5)
p.G119R 3.09 (0.68–14.13) 0.15 Probably damaging 26.1 22.0–28.1 100 (4/4)
p.P553Sb 2.69 (1.11–6.54) 0.03 Benign 46.3 32.8–70.8 0 (0/9)
p.K441R 1.43 (0.74–2.75) 0.35 Benign 41.7 23.6–56.6 11 (2/18)
p.G261D 0.93 (0.38–2.27) 1.00 Benign 48.7 39.6–64.4 0 (0/12)
p.T300A 0.77 (0.21–2.88) 0.74 Benign 48.4 34.6–66.1 0 (0/7)
p.R202I 0.35 (0.11–1.10) 0.07 Possibly damaging 46.1c 35.1–62.6c 0 (0/11)c
p.R406Hd 0.10 (0.01–0.85) 0.02 Possibly damaging 47.7 46.2–50.5 0 (0/3)
AAMD, advanced age-related macular degeneration; CFI, complement factor I gene; FI, serum factor I.
aPercentage (and number) of subjects with the variant who have low serum FI levels (<29.3 µg/ml).
bRisk variant.
cOne individual was a compound heterozygote (p.R202I/p.A356P). This individual had a normal serum FI level (35.6 µg/ml) and is not shown in this table.
dProtective variant.
Figure 2. Comparison of serumFI levels in advanced age-relatedmacular degeneration (AAMD) and non-AAMD/CFI rare variant groups. SerumFI levelsweremeasured for
209 individuals. Themean of the 79 patients with AAMD and rare genetic CFI variants was 34.8 μg/ml (95% CI: 31.8–37.8). For the 48 AAMDpatients with no rare genetic CFI
variants, the mean was 40.1 μg/ml (95% CI: 37.8–42.4). In those without AAMD and with genetic variants (n = 35), the mean was 44.8 μg/ml (95% CI: 41.8–47.9). In the non-
AAMD without a genetic variant (n = 47) the mean was 39.2 μg/ml (95% CI: 37.2–41.2). The box plots show medians and quartiles. The means are shown as black circles.
Individual patient values are shown as diamonds. Analysis of variance was undertaken by one-way ANOVA with post hoc analysis. The lower limit of normal is
demonstrated by a dotted line (29.3 μg/ml) (*P = 0.03, **P < 0.001). Subjects with low serum FI levels are shown as n (%).
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levels ranging from 10.5 to 23.5 and one had a normal value. The
previously reported p.G119R risk variant (9,11)was not significant
in our study (P = 0.15) but had low FI in all individuals tested
(Table 2 and Fig. 4).
There were no confirmed cases of aHUS in our cohort of AMD
patients with CFI variants. It is believed that a confluence of rare
genetic variants and common genetic polymorphisms and hap-
lotypes in addition to a triggering stimulus, such as infection or
pregnancy, are required for aHUS to manifest (18). It is known
that different CFH risk haplotypes exist for aHUS and AMD (32).
It is possible that differences in the background complotype
(33) of an individual may determine the ultimate clinical disease
process. Further investigation is required to fully understand the
genetic differences between CFI-mediated aHUS and AMD.
Individuals carrying one of four variants, p.G162D, p.A240G,
p.D310E, and p.K441R, had both normal and low FI levels. FI is
an acute phase protein with IL6 (34) and IFNγ (35,36) increasing
its secretion. In those individuals with no genetic variants, we
demonstrated up to an approximate 2-fold variation in levels in
keepingwith previous studies (Fig. 2) (37).With such natural vari-
ability, it is possible that the effects of a heterozygous variant
may be masked in some patients by the wide normal range,
thus requiring care when interpreting serum levels in isolation.
However, a value <29.3 µg/ml is a strong indicator of risk for AMD.
While the functional effect of type 1CFI genetic variants in the
pathogenesis of AMD seems apparent, the effect of the rare gen-
etic variants which do not result in a failure of secretion (type 2
variant) remains unclear. Of the type 2 variants, p.P553S, classi-
fied as benign by PolyPhen2, increased risk for AMD (OR 2.7),
while p.R406H classified as possibly damaging, was protective
(OR 0.10). Functional analyses of the type 2 variants p.G261D
and p.R406H have not shown a loss of activity (38,39), while fur-
ther analysis of the remaining variant proteins with serum anti-
genic levels in the normal range will be required to assess their
role in disease. We are taking two approaches to address this
question: expression of themutant in question and development
of a test employing an individual’s serum that closely correlates
with antigenic levels.
There was no significant difference in FI levels in AAMD and
non-AAMD individuals without a CFI genetic variant in keeping
with a causative role for the genetic variants. In those individuals
without a rare genetic variant, we also assessed FI levels in the
context of a common CFI variant previously associated with
AMD (rs10033900) (12,40).We did not demonstrate significant dif-
ferences in FI levels by rs10033900 genotype.
FI is required to downregulate the alternative pathway of
complement activation and complete FI deficiency is associated
with a consumptive deficiency of C3 and consequently recurrent
infections, not immunopathology (13,14). It is informative that in
our study no individual with AMDwas seen to have complete de-
ficiency of FI. One individual with two genetic variants (P50A/
V543A), who we assume to be a compound heterozygote, had
very low, although detectable, FI levels (7.3 µg/ml). Interestingly,
this patient’s C3 level was normal (0.94 mg/ml), and it can be as-
sumed that even in this individual there is sufficient functional FI
present. In the complete absence of FI, no efficient breakdown of
C3b to iC3b and ultimately C3c and C3dg is possible. The forma-
tion of iC3b and its interaction with CR3 and CR4 is one of the
most potent complement inflammatory effects (14). In a CFI
knockoutmouse, C3 circulates as C3bwith no evidence of further
degradation products (e.g. iC3b, C3dg) (41). This mimics the
Figure 3. The association between groups defined by advanced age-related macular degeneration (AAMD)/CFI rare variant status and low serum FI level. Unadjusted
analyses: estimated odds ratio of the association between AAMD/CFI rare variant status and low serum FI (≤29.3 µg/ml). Adjusted analyses: estimated odds ratio of
the association between AAMD/CFI rare variant status and low serum FI (≤29.3 µg/ml) after adjusting for age at the time of blood sample (≤80, >80 yr), gender, body
mass index (<25, ≥25) and smoking status (never, ever). All analyses used using exact binomial probabilities based on the exact option of PROC FREQ in SAS 9.3. OR:
odds ratio; CI: confidence interval. aOR > 1 indicates that low serum FI increases risk, while OR < 1 indicates that low serum FI is protective.
Table 3.Distribution of variables according to serumFI level among all
subjects with a rare CFI variant
Variable Low serum
FI (n = 35)
Normal/high
serum FI (n = 79)
P-valuea
Age at sample (mean ± SD) 76.6 ± 9.5 75.9 ± 8.1 0.68
Gender (n, % male) 19 (54.3) 24 (30.4) 0.02
AMD groupsb
Non-AAMD 2 (5.7)c 33 (41.8) 5.6 × 10−5
AAMD 33 (94.3) 46 (58.2)
CFI, complement factor I (gene); FI, factor I (protein).
Variables are presented as n (%) or (mean ± SD).
aP-values calculated as follows: one-way ANOVA for age at sample; Fisher’s exact
test for AMD Groups.
bAMD classifications: non-AAMD: no AMD, early or intermediate AMD defined as
subjects with CARMS grades (17), 2 or 3a in at least one eye and no advanced
disease in the worst eye; AAMD, advanced AMD defined as subjects with
CARMS grades 3b, 4 or 5 in at least one eye.
cFor the two individuals in the non-AAMD group with a type 1 mutation, retinal
screening at the beginning of the study revealed grade 3 maculopathy at ages 42
and 73, respectively. With additional follow-up time, the 73-year-old individual
has progressed to grade 4 (advanced dry AMD).
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situation in humans with complete deficiency of FI. These C3b
metabolites have been demonstrated to be critical in the develop-
ment of membranoproliferative glomerulonephritis in a mouse
model of disease (41,42). Our study is in keeping with a hyperin-
flammatory complement phenotype causing AMD at least in part
mediated through iC3b (14).
Our hypothesis to explain the AMD/FI association is
straightforward: increased complement alternative pathway
activity in the retina results from or is secondary to low FI levels;
i.e. for a given degree of retinal injury or damage, there is an ex-
cessive (undesirable) degree of complement activation which is
particularly damaging to the retina. The hyperinflammatory re-
sponse may affect the retinal pigment epithelium, drusen, or
the local vasculature, leading to an acceleration of the disease
process. This conforms to established complement risk factors
for AMD which can cause an accelerated C3b feedback cycle.
Unsurprisingly, it has long been known that elevating serum
FI concentration can downregulate this C3b amplification
loop (43).
It is interesting to note, although entirely in keeping with CFI-
associated aHUS (18), that even in AAMD cases with type I CFI
mutations, 29 of 32 had normal C3 levels. C3 is also an acute
phase protein and not a sensitive marker of complement activa-
tion. In these patients, however, there was a positive correlation
between FI levels and C3 levels in keeping with the regulatory ac-
tivity of FI.
Rare genetic variants in CFI have been associated with AAMD
(9–11); however, a majority are missense mutations of uncertain
clinical relevance. This inability to correctly identify functionally
significant genetic variants impairs our understanding of the dis-
ease pathogenesis and is an impediment to personalized man-
agement of AMD. Our data underscore the pathogenic role of
CFI genetic variants in AMD. Measuring serum antigenic levels
of FI provides a practical, low cost, screening tool for AMD in
the clinic. We suggest that this group of patients with both a
rare CFI variant and low serum FI is most likely to benefit from
complement inhibitory therapy (15) or supplementation with FI
(16). We note that the recent MAHALO study examining the role
of lampalizumab (anti-factor D complement regulator) in AMD
reported success in a subgroup of patients with the common
CFI variant (15). Identification of individuals with type I CFImuta-
tions will allow targeting of those most likely to benefit from
complement inhibitory therapy and pave the way for persona-
lized medicine in AMD (44).
Materials and Methods
Study population
All individuals in this study were Caucasian participants in on-
going genetic and epidemiologic studies ofmacular degeneration
who signed consent forms for the study approved by the
Figure 4. Serum FI levels by rare CFI genetic variant. The serum FI levels of all individuals stratified by CFI genetic variant. CFI variants with counts <5 in the combined
sequencing panel are colored red. Variants with counts ≥5 are blue. Genetic variants in individuals with AAMD are represented by afilled diamond and comparison group
without AAMD are shownwith an unfilled diamond. Genetic variants are grouped into benign, possibly damaging, probably damaging, or loss of function as predicted by
PolyPhen2. Two individuals were compound heterozygotes (p.V543A/p.P50A; p.A356P/p.R202I). p.R202I and p.V543Awere predicted to be possibly damaging while A356P
and P50Awere predicted to be probably damaging. The blackfilled diamonds represent the 95 individuals (47 non-AAMD, 48AAMD)with noCFI variants. The lower limit of
normal is demonstrated by a dotted line (29.3 μg/ml).
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institutional review board (6,7,10,17,44–50). We determined pres-
ence or absence of AMD based on clinical examination and fun-
dus photography. JMS assigned grades for no AMD, early,
intermediate and advanced stages of AMD using the Clinical
Age-Related Maculopathy Grading System (CARMS) (17) as fol-
lows: Grade 1-no drusen or only a few small drusen; Grade 2-
early maculopathy with small, hard drusen (2a) or retinal pig-
ment alteration (2b) or both (2c); Grade 3-intermediate AMD
with several intermediate drusen and/or presence of large, soft
drusen; and AAMDwith Grade 3b-drusenoid retinal pigment epi-
thelial detachment, Grade 4-central or non-central geographic
atrophy, and Grade 5-neovascular AMD.
Serum samples and complement analysis
We obtained serum samples according to a standard protocol
and stored them at −140°C (51). We measured FI levels by radial
immunodiffusion with anti-human antibodies specific for FI in
1% agarose gels (normal range 29.3–58.5 µg/ml) (51,52). C3 was
measured by standard clinical laboratory nephelometric meth-
ods (normal range 0.79–1.67 mg/ml) (51).
Sequencing the CFI gene
Figure 1 displays the source of all sample subsets described in
this manuscript. To elaborate, we previously reported a targeted
sequencing study of samples from 1676 individuals with AAMD
and 745 subjects without any signs of AMD, covering 681 genes
including CFI (10). We expanded this cohort by sequencing add-
itional independent samples of 194 cases and 213 controls
using the same targeted sequencing design (10). In that cohort
of total 2828 samples, we identified 172 individuals who had at
least one rare allele in CFI. We further extended this search for
variants by conducting Sanger sequencing of the CFI gene in a
separate and independent cohort with a total sample size of
838 (396 persons with AAMD and 442 without any signs of AMD
with grade 1 in both eyes or grade 1 in one eye and grade 2 in
the fellow eye). Using the same primers previously shown to pro-
duce high quality amplicons covering the entire exon sequence
and adjacent splice sites (10), we sequenced forward and reverse
PCR primers via capillary electrophoresis employing ABI Prism
3730xl DNA analyzers (Applied Biosystems, Foster City, CA,
USA) at Beckman Coulter Genomics. Chromatograms were as-
sembled using CONSED and polymorphisms were detected
using polyphred 5.04 (University of Washington), with propri-
etary improvements to increase sensitivity while maintaining
specificity.We identified an additional 59 individuals in the Sang-
er sequencing study who had a least one rare allele in CFI. (Sup-
plementary Material, Tables S1–S4 show the results of the
combined sequencing experiments).
Serum sample selection
In order to explore the effects of disease and CFI rare variants on
serum FI levels, we first identified individuals with a variant and
with AAMD for whom serum samples were available (n = 79). We
identified three comparison groups from the sequenced indivi-
dualswith similarmean ages at the time of blood draw compared
to advancedAMDcases carrying avariant: (i) subjectswithAAMD
but no variant (n = 48); (ii) subjects without AAMD and without a
variant (n = 47); and (iii) subjects without AAMD but with a vari-
ant (n = 35) (Fig. 2). The total sample comprised 209 subjects,
with 114 carrying rare CFI variants.
Statistical analysis
We obtained information on covariates including age at blood
sample collection, gender, BMI and smoking from our AMD
Figure 5. Comparison of serumFI levels by in silico functional prediction. Themeanof the 76 individualswith rare geneticCFI variants predicted to be either benign or possibly
damagingwas 43.1 μg/ml (95%CI: 40.8–45.5). The 36 individualswith probably damaging or loss-of-functionCFI variants had amean serumFI level of 27.7 μg/ml (95%CI: 24.0–
31.4). In thosewithno rare genetic variants inCFI (n = 95), themeanwas39.7 μg/ml (95%CI: 38.2–41.2). The box plots showmedians andquartiles. Themeansare shownasdark
circle. Individual patient values are shown as diamonds. The two individuals carrying compound heterozygous mutations were not included in this analysis. Analysis of
variance was undertaken by one-way ANOVAwith post hoc analysis (***P< 0.001). The lower limit of normal is demonstrated by a dotted line (29.3 μg/ml).
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study databases as previously described (6,10,17,44–50). We
coded BMI and smoking as dichotomous variables: BMI (<25,
≥25), smoking (never smoked, ever smoked). Serum FI status
was coded as a dichotomous variable according to laboratory nor-
mal ranges (51), with serum FI under 29.3 µg/ml being classified
as low serumFI level. The relationship between age at blood sam-
ple collection and serumFI level with AMD/CFI rare variant status
was assessed using a one-way ANOVA. Pearson’s Chi-square test
was used for gender, BMI, smoking status and low serum FI level.
To calculate the OR of the association between AAMD/CFI rare
variant status and low serum FI, we classified individuals accord-
ing to their age (<80 yrs or 80+ yrs), gender, BMI and smoking sta-
tus. The OR for non-adjusted and covariate adjusted associations
were computed using exact binomial probabilities by PROC FREQ
procedure with EXACT option of SAS 9.3.
For analyses of subjects with a rare CFI genetic variant, we
used binary logistic regression analysis to analyze the associ-
ation between a subject’s AAMD status and serum FI, controlling
for age at blood sample collection, gender, smoking and BMI sta-
tus. Subjects with AAMD were compared to individuals with a
rare CFI variant but without AAMD. For the rare CFI variants (de-
fined as a frequency <1% in either the AAMD or non-AAMD
groups), we tested variants with a frequency ≥5 among AAMD
and non- AAMD groups separately. For variants with frequency
<5, we grouped variants into categories based on PolyPhen2
(53), and analyzed them for significance within each group. We
estimated allele frequencies of CFI variants using PLINK (54),
and evaluated association of single variant or a group of variants
with AAMD by Fisher’s exact test.
Supplementary Material
Supplementary Material is available at HMG online.
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